These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival. Yang J; Griffiths M; Nies MK; Brandal S; Damico R; Vaidya D; Tao X; Simpson CE; Kolb TM; Mathai SC; Pauciulo MW; Nichols WC; Ivy DD; Austin ED; Hassoun PM; Everett AD BMC Med; 2020 Oct; 18(1):268. PubMed ID: 33019943 [TBL] [Abstract][Full Text] [Related]
5. Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency. Sweatt AJ; Miyagawa K; Rhodes CJ; Taylor S; Del Rosario PA; Hsi A; Haddad F; Spiekerkoetter E; Bental-Roof M; Bland RD; Swietlik EM; Gräf S; Wilkins MR; Morrell NW; Nicolls MR; Rabinovitch M; Zamanian RT Chest; 2021 Oct; 160(4):1442-1458. PubMed ID: 34181952 [TBL] [Abstract][Full Text] [Related]
6. Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis. Samokhin AO; Hsu S; Yu PB; Waxman AB; Alba GA; Wertheim BM; Hopkins CD; Bowman F; Channick RN; Nikolic I; Faria-Urbina M; Hassoun PM; Leopold JA; Tedford RJ; Ventetuolo CE; Leary PJ; Maron BA J Heart Lung Transplant; 2020 Apr; 39(4):289-299. PubMed ID: 31952977 [TBL] [Abstract][Full Text] [Related]
7. Pediatric pulmonary hypertension: insulin-like growth factor-binding protein 2 is a novel marker associated with disease severity and survival. Griffiths M; Yang J; Nies M; Vaidya D; Brandal S; Williams M; Matsui EC; Grant T; Damico R; Ivy D; Austin ED; Nichols WC; Pauciulo MW; Lutz K; Rosenzweig EB; Hirsch R; Yung D; Everett AD Pediatr Res; 2020 Dec; 88(6):850-856. PubMed ID: 32927467 [TBL] [Abstract][Full Text] [Related]
8. Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension. Daly CM; Griffiths M; Simpson CE; Yang J; Damico RL; Vaidya RD; Williams M; Brandal S; Jone PN; Polsen C; Ivy DD; Austin ED; Nichols WC; Pauciulo MW; Lutz K; Nies MK; Rosenzweig EB; Hirsch R; Yung D; Everett AD J Am Heart Assoc; 2021 Oct; 10(20):e021409. PubMed ID: 34622662 [TBL] [Abstract][Full Text] [Related]
9. Circulating High Mobility Group Box-1 Does Not Predict Pulmonary Arterial Hypertension in Children with Congenital Heart Disease: A Prospective Cohort Study. Caracci B; Pehora C; Benson L; Steinberg BE; Goldenberg NM; Taylor K J Cardiothorac Vasc Anesth; 2024 Oct; 38(10):2356-2361. PubMed ID: 39095209 [TBL] [Abstract][Full Text] [Related]
10. Resistin predicts disease severity and survival in patients with pulmonary arterial hypertension. Gao L; Skinner J; Nath T; Lin Q; Griffiths M; Damico RL; Pauciulo MW; Nichols WC; Hassoun PM; Everett AD; Johns RA Respir Res; 2024 Jun; 25(1):235. PubMed ID: 38844967 [TBL] [Abstract][Full Text] [Related]
12. Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension. Zheng YG; Yang T; He JG; Chen G; Liu ZH; Xiong CM; Gu Q; Ni XH; Zhao ZH Clin Cardiol; 2014 Jun; 37(6):365-70. PubMed ID: 25068163 [TBL] [Abstract][Full Text] [Related]
13. Is pulmonary vascular resistance index better than pulmonary vascular resistance in predicting outcomes in pulmonary arterial hypertension? Khirfan G; Li M; Wang X; Dweik RA; Heresi GA; Tonelli AR J Heart Lung Transplant; 2021 Jul; 40(7):614-622. PubMed ID: 33962868 [TBL] [Abstract][Full Text] [Related]
14. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension. D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498 [TBL] [Abstract][Full Text] [Related]
15. Serial Measurements of N-Terminal Pro-B-Type Natriuretic Peptide Serum Level for Monitoring Pulmonary Arterial Hypertension in Children. Said F; Haarman MG; Roofthooft MTR; Hillege HL; Ploegstra MJ; Berger RMF J Pediatr; 2020 May; 220():139-145. PubMed ID: 32113658 [TBL] [Abstract][Full Text] [Related]
17. Electrocardiographic Abnormalities and Their Association with Outcomes in Randomized Clinical Trials of Pulmonary Arterial Hypertension. Minhas J; Moutchia J; Al-Naamani N; Mazurek JA; Holmes JH; Appleby D; Smith KA; Fritz JS; Pugliese SC; Palevsky HI; Kawut SM Ann Am Thorac Soc; 2024 Jun; 21(6):858-865. PubMed ID: 38241602 [No Abstract] [Full Text] [Related]
18. Hypochloremia Is a Noninvasive Predictor of Mortality in Pulmonary Arterial Hypertension. Prins KW; Kalra R; Rose L; Assad TR; Archer SL; Bajaj NS; Weir EK; Prisco SZ; Pritzker M; Lutsey PL; Brittain EL; Thenappan T J Am Heart Assoc; 2020 Mar; 9(5):e015221. PubMed ID: 32079477 [TBL] [Abstract][Full Text] [Related]
19. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension. Wronski SL; Mordin M; Kelley K; Anguiano RH; Classi P; Shen E; Manaker S Lung; 2020 Feb; 198(1):65-86. PubMed ID: 31722043 [TBL] [Abstract][Full Text] [Related]